indinavir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
HIV protease inhibitors 1437 150378-17-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • indinavir
  • indinavir sulphate
  • crixivan
  • indinavir sulfate
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.
  • Molecular weight: 613.80
  • Formula: C36H47N5O4
  • CLOGP: 3.68
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 4
  • TPSA: 118.03
  • ALOGS: -4.11
  • ROTB: 12
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 27.21 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 65 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.82 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.36 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,TEK,TGFBR1 24
kinase-selectivity-class AXL,BRAF,EPHB4,GRK2 4
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 26.424 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
rat-kpuu-brain Rat brain Kpuu 0.012 % High 1

Approvals:

DateAgencyCompanyOrphan
March 13, 1996 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Viral mutation identified 266.45 90.08 36 344 1989 90626078
Drug resistance 163.26 90.08 35 345 30414 90597653
Virologic failure 103.51 90.08 16 364 2208 90625859
Pathogen resistance 101.69 90.08 19 361 8096 90619971

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 879.41 100.36 147 1614 3303 42616271
Mitochondrial toxicity 761.34 100.36 125 1636 2490 42617084
Eyelid ptosis 644.62 100.36 125 1636 6536 42613038
Diplopia 500.68 100.36 124 1637 20192 42599382
Progressive external ophthalmoplegia 406.49 100.36 67 1694 1344 42618230
Virologic failure 169.27 100.36 38 1723 3956 42615618
Ophthalmoplegia 167.85 100.36 34 1727 2166 42617408
Pathogen resistance 125.15 100.36 37 1724 11413 42608161
Dysphagia 114.59 100.36 57 1704 72662 42546912
Viral mutation identified 110.60 100.36 26 1735 3305 42616269

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 959.86 95.55 145 1668 4379 110583107
Mitochondrial toxicity 841.89 95.55 124 1689 3121 110584365
Eyelid ptosis 666.87 95.55 124 1689 13203 110574283
Diplopia 520.02 95.55 123 1690 41771 110545715
Progressive external ophthalmoplegia 467.92 95.55 67 1746 1353 110586133
Viral mutation identified 297.40 95.55 53 1760 4366 110583120
Virologic failure 252.67 95.55 47 1766 4905 110582581
Ophthalmoplegia 176.59 95.55 33 1780 3517 110583969
Drug resistance 175.60 95.55 56 1757 56318 110531168
Pathogen resistance 172.80 95.55 43 1770 17629 110569857
Multiple-drug resistance 138.38 95.55 34 1779 13201 110574285
Dysphagia 124.16 95.55 57 1756 153543 110433943

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AE02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Protease inhibitors
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:64946 anti-HIV agent
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
MeSH PA D017320 HIV Protease Inhibitors
MeSH PA D019380 Anti-HIV Agents
CHEBI has role CHEBI:35660 HIV protease inhibitor

Related Drugs by ATC class:

J05AE Protease inhibitors 10 drugs
amprenaviratazanavirdarunavirensitrelvirfosamprenavirnelfinavirnirmatrelvirritonavirsaquinavirtipranavir

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Prevention of HIV Infection after Exposure off-label use
Pyuria contraindication 4800001 DOID:1439
Hypercholesterolemia contraindication 13644009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Cirrhosis of liver contraindication 19943007 DOID:5082
Blood in urine contraindication 34436003
Hemolytic anemia contraindication 61261009 DOID:583
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Hemophilia contraindication 90935002
Kidney stone contraindication 95570007
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Hypertriglyceridemia contraindication 302870006
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.82 acidic
pKa2 12.01 acidic
pKa3 6.96 Basic
pKa4 3.56 Basic
pKa5 2.83 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Thromboxane-A synthase Enzyme IC50 5.73 DRUG MATRIX
Substance-K receptor GPCR Ki 5.77 DRUG MATRIX
Multidrug and toxin extrusion protein 1 Transporter IC50 5.77 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 5.11 CHEMBL
Cytochrome P450 3A4 Enzyme IC50 6.40 DRUG MATRIX
Pol polyprotein Enzyme INHIBITOR Ki 10.15 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein IC50 9.22 WOMBAT-PK
Protease Enzyme Ki 8.48 CHEMBL
Protease Enzyme Ki 9.27 CHEMBL
Protease Enzyme Ki 9.06 CHEMBL
Protease Enzyme Ki 9.42 CHEMBL

External reference:

IDSource
4024026 VUID
N0000022031 NUI
D00897 KEGG_DRUG
180683-37-8 SECONDARY_CAS_RN
157810-81-6 SECONDARY_CAS_RN
4020965 VANDF
4024026 VANDF
C0376637 UMLSCUI
CHEBI:44032 CHEBI
MK1 PDB_CHEM_ID
CHEMBL5483011 ChEMBL_ID
CHEMBL1735 ChEMBL_ID
D019469 MESH_DESCRIPTOR_UI
DB00224 DRUGBANK_ID
12684 IUPHAR_LIGAND_ID
5W6YA9PKKH UNII
5362440 PUBCHEM_CID
114289 RXNORM
4875 MMSL
6513 MMSL
d03985 MMSL
005733 NDDF
005734 NDDF
108695003 SNOMEDCT_US
108696002 SNOMEDCT_US
372529006 SNOMEDCT_US
5W6YA9PKKH INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CRIXIVAN HUMAN PRESCRIPTION DRUG LABEL 1 16590-064 CAPSULE 400 mg ORAL NDA 28 sections
CRIXIVAN HUMAN PRESCRIPTION DRUG LABEL 1 21695-366 CAPSULE 400 mg ORAL NDA 27 sections
CRIXIVAN HUMAN PRESCRIPTION DRUG LABEL 1 53808-0661 CAPSULE 400 mg ORAL NDA 27 sections